Skip to main content Skip to secondary navigation

Porter Alliance for Innovative Medicines (Deerfield)

Main content start

Porter Alliance for Innovative Medicines is a collaboration between Stanford and Deerfield Management Company, an investment firm dedicated to advancing healthcare, to accelerate the translation of research in Stanford faculty laboratories into clinical therapeutics. Porter Alliance is a Deerfield company that will support Stanford’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development.

Learn more on the Porter Alliance website

 

Overview of Porter Alliance

Porter Alliance will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases.

Through Porter Alliance, Deerfield has committed up to $130 million in initial funding to support advanced translational research projects from Stanford labs. With IMA’s help, Stanford researchers will have the ability to submit proposals for consideration by Deerfield. Accepted projects will include a development plan aimed at achieving IND readiness. Deerfield will provide funding & operational support for accepted projects. Successful projects that achieve IND-enabled status may be eligible for additional capital investments into spin-off companies that emerge from Porter Alliance projects. Under the terms of the agreement, Porter Alliance will receive an option to license any IP resulting from the funded projects at Stanford.

For more information, visit the Porter Alliance for Innovative Medicines website

Questions about Porter Alliance? Contact Paul Humphries (phumphries@stanford.edu), Alliance Director at the Innovative Medicines Accelerator